Comparison of adverse events during 5‐fluorouracil versus 5‐fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer

Abstract

The incremental harms of adjuvant chemotherapy with 5FU/oxaliplatin versus 5FU alone were modest in patients with stage III colon cancer who were insured by Medicare and Medicaid. The additional harms in patients aged ≥ 75 years largely were restricted to outpatient events and did not extend to an increased rate of hospitalization or early death.